Neovascular Age-related Macular Degeneration (nAMD)NCT06929143
A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
An observational study of Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME), run by Bayer at 1 site in Japan.
Trial summary
This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied. In observational studies, only observations are made without participants receiving any advice or any changes to healthcare. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
- What is being tested?
- Aflibercept (Eylea, BAY86-5321)
- Type of treatment
- Injection or infusion
- How many people
- 3,000 participants
- Where
- 1 siteJapan
- Study dates
- 14 Apr 2025to 30 Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Samples will be taken from the DeSC healthcare insurance database. This database contains information of 12 million individuals and has in a previous study been found to be demographically distributed in a similar manner to the Japanese population.
Who may be able to join
- Patients who are prescribed aflibercept 8 mg during the observable period from the collected data.
Who cannot join
- Patients in the nAMD cohort or nAMD and DME cohort who have the ICD-10 codes for nAMD who are aged <40 years old.
- Patients in the DME cohort or others who are aged <18 years old.
- Female patients who have any pregnancy-related records.
- Patients who do not have at least 365 days of continuous enrollment in the database.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Real-world Utilization Patterns of Aflibercept 8 mg in Japan: a Retrospective Descriptive Study Using the Claims Database
This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied. In observational studies, only observations are made without participants receiving any advice or any changes to healthcare.
The eye disorders, nAMD and DME, affect the macula, the central part of the retina at the back of the eye. This leads to blurry vision or blind spots, making everyday activities like reading or sewing difficult. While nAMD is linked to aging, DME is related to diabetes. Both conditions require similar treatment to help improve vision.
Read more
Aflibercept 8 milligrams (mg) is already approved in Japan for doctors to prescribe to people with nAMD or DME. It is a drug injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF), which causes abnormal growth and leakage of blood vessels at the back of the eye.
The participants in this study are already receiving treatment with aflibercept 8 mg as part of their regular care from their doctors.
There is limited data available on the use of aflibercept 8 mg in Japan. Data from routine medical practice will inform treatment in Japanese and other Asian populations.
The main purpose of this study is to learn more about the disease and patient characteristics of Japanese participants with nAMD and/or DME who receive aflibercept 8 mg during their routine healthcare, and how they use it.
To learn this, the study will use 2 methods:
Method 1: Researchers will study the health details of participants when they first started aflibercept 8 mg.
Method 2: Researchers will study the participants' data collected over 1 year to see how they used aflibercept 8 mg.
The data will come from a claims database called DeSC Healthcare Inc. The data will be collected from April 2023 to March 2025 for Method 1, and from April 2023 to March 2026 for Method 2.
Researchers will only look at the information from participants in Japan.
In this study, only available data from routine care are collected. No visits or tests are required as part of this study.
- Being tested
- Aflibercept (Eylea, BAY86-5321)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Aflibercept (Eylea, BAY86-5321)Drug
8 mg (0.07 mL) intravitreal (IVT) injection (114.3mg/mL).
| Study group | Role | What they receive |
|---|---|---|
| Patients with neovascular Age-related Macular Degeneration (nAMD) | Patients with any International Classification of Diseases, Tenth revision (ICD-10) codes for nAMD or possible nAMD within the same month of the cohort entry date (except for patients who meet the nAMD/DME cohort definition). Receives: Drug: Aflibercept (Eylea, BAY86-5321) | |
| Patients with Diabetic Macular Edema (DME) | Patients with any ICD-10 codes for DME or possible DME within the same month of the cohort entry date (except for patients who meet the nAMD/DME cohort definition). Receives: Drug: Aflibercept (Eylea, BAY86-5321) | |
| Patients with nAMD/DME | Patients who have ICD-10 codes for nAMD, possible nAMD, DME, and possible DME within the same month of the cohort entry date. Receives: Drug: Aflibercept (Eylea, BAY86-5321) | |
| Other patients | Patients with no ICD-10 codes for nAMD, possible nAMD, DME, and possible DME within the same month of the cohort entry date. Receives: Drug: Aflibercept (Eylea, BAY86-5321) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Description of baseline characteristics of patients with nAMD or DME who initiated aflibercept 8 mg under real-world conditions.
Measured: At baseline.
Description of the longitudinal patterns of treatment interval of patients with nAMD or DME who initiated aflibercept 8 mg.
Measured: Within 12 months.
Secondary outcomes (4)
Change of treatment interval of patients with nAMD or DME who are treated with other anti-VEGF therapy.
Measured: Before and 12 months after initiation of aflibercept 8 mg.
Number of injections of aflibercept 8 mg in patients with nAMD or DME.
Measured: Within 3 months, 6 months, and 12 months after the first prescription date of aflibercept 8 mg.
Predicting factors of the patterns of the treatment interval of aflibercept 8 mg in patients with nAMD or DME.
Measured: Within 12 months.
Proportion of patients who continue the aflibercept 8 mg.
Measured: Within 12 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Apr 2025
- Study start14 Apr 2025
- Primary completion30 Jul 2027 (estimated)
- Study completion30 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neovascular Age-related Macular Degeneration (nAMD)Studies of the same condition, open and under way.
- More trials run by BayerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bayer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06929143
- Sponsor's protocol ID
- 22905
- Status last verified
- May 2026
- First submitted
- 8 Apr 2025
- Last updated
- 12 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real-world Utilization Patterns of Aflibercept 8 mg in Japan: a Retrospective Descriptive Study Using the Claims Database
- ClinicalTrials.gov ID
- NCT06929143
- Acronym / sponsor ID
- 22905
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- BayerIndustry (pharma, biotech, devices)
- Study start
- 14 Apr 2025 (actual)
- Primary completion
- 30 Jul 2027 (estimated)
- Study completion
- 30 Jul 2027 (estimated)
- First posted
- 16 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied. In observational studies, only observations are made without participants receiving any advice or any changes to healthcare.
The eye disorders, nAMD and DME, affect the macula, the central part of the retina at the back of the eye. This leads to blurry vision or blind spots, making everyday activities like reading or sewing difficult. While nAMD is linked to aging, DME is related to diabetes. Both conditions require similar treatment to help improve vision.
Aflibercept 8 milligrams (mg) is already approved in Japan for doctors to prescribe to people with nAMD or DME. It is a drug injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF), which causes abnormal growth and leakage of blood vessels at the back of the eye.
The participants in this study are already receiving treatment with aflibercept 8 mg as part of their regular care from their doctors.
There is limited data available on the use of aflibercept 8 mg in Japan. Data from routine medical practice will inform treatment in Japanese and other Asian populations.
The main purpose of this study is to learn more about the disease and patient characteristics of Japanese participants with nAMD and/or DME who receive aflibercept 8 mg during their routine healthcare, and how they use it.
To learn this, the study will use 2 methods:
Method 1: Researchers will study the health details of participants when they first started aflibercept 8 mg.
Method 2: Researchers will study the participants' data collected over 1 year to see how they used aflibercept 8 mg.
The data will come from a claims database called DeSC Healthcare Inc. The data will be collected from April 2023 to March 2025 for Method 1, and from April 2023 to March 2026 for Method 2.
Researchers will only look at the information from participants in Japan.
In this study, only available data from routine care are collected. No visits or tests are required as part of this study.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Patients with neovascular Age-related Macular Degeneration (nAMD) | – | Drug: Aflibercept (Eylea, BAY86-5321)Patients with any International Classification of Diseases, Tenth revision (ICD-10) codes for nAMD or possible nAMD within the same month of the cohort entry date (except for patients who meet the nAMD/DME cohort definition). |
| Patients with Diabetic Macular Edema (DME) | – | Drug: Aflibercept (Eylea, BAY86-5321)Patients with any ICD-10 codes for DME or possible DME within the same month of the cohort entry date (except for patients who meet the nAMD/DME cohort definition). |
| Patients with nAMD/DME | – | Drug: Aflibercept (Eylea, BAY86-5321)Patients who have ICD-10 codes for nAMD, possible nAMD, DME, and possible DME within the same month of the cohort entry date. |
| Other patients | – | Drug: Aflibercept (Eylea, BAY86-5321)Patients with no ICD-10 codes for nAMD, possible nAMD, DME, and possible DME within the same month of the cohort entry date. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Samples will be taken from the DeSC healthcare insurance database. This database contains information of 12 million individuals and has in a previous study been found to be demographically distributed in a similar manner to the Japanese population.
Key inclusion criteria (1 listed)
- Patients who are prescribed aflibercept 8 mg during the observable period from the collected data.
Key exclusion criteria (4 listed)
- Patients in the nAMD cohort or nAMD and DME cohort who have the ICD-10 codes for nAMD who are aged <40 years old.
- Patients in the DME cohort or others who are aged <18 years old.
- Female patients who have any pregnancy-related records.
- Patients who do not have at least 365 days of continuous enrollment in the database.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Aflibercept (Eylea, BAY86-5321)8 mg (0.07 mL) intravitreal (IVT) injection (114.3mg/mL). | Drug | Other patients, Patients with Diabetic Macular Edema (DME), Patients with nAMD/DME, Patients with neovascular Age-related Macular Degeneration (nAMD) |
Primary outcome
Description of baseline characteristics of patients with nAMD or DME who initiated aflibercept 8 mg under real-world conditions.
Time frame: At baseline.
Description of the longitudinal patterns of treatment interval of patients with nAMD or DME who initiated aflibercept 8 mg.
Time frame: Within 12 months.
4 secondary outcomes
Change of treatment interval of patients with nAMD or DME who are treated with other anti-VEGF therapy.
Time frame: Before and 12 months after initiation of aflibercept 8 mg.
Number of injections of aflibercept 8 mg in patients with nAMD or DME.
Time frame: Within 3 months, 6 months, and 12 months after the first prescription date of aflibercept 8 mg.
Predicting factors of the patterns of the treatment interval of aflibercept 8 mg in patients with nAMD or DME.
Time frame: Within 12 months.
Proportion of patients who continue the aflibercept 8 mg.
Time frame: Within 12 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2026.
- Individual participant dataSharing planned: No. Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Related trials for Neovascular Age-related Macular Degeneration (nAMD)
RecruitingPhase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
Not yet recruitingPhase 2
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration(nAMD)
RecruitingPhase 1
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
nAMD
Active, not recruitingPhase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
RecruitingPhase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME), run by Bayer at 1 site in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Description of baseline characteristics of patients with nAMD or DME who initiated aflibercept 8 mg under real-world conditions. (time frame: At baseline.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.